Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
The purpose of this research is to characterize the effect of teriflunomide on the activation
 of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro
 identified effects of teriflunomide on the expression of B-cell activation markers,
 costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then
 be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated
 with this medication.
Inclusion Criteria:

 -  confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,

 -  age 18-55,

 -  an extended disability status score (EDSS) of 1.5-5.5.

 Exclusion Criteria:

 - Previous treatment with DMT.